Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. - Wikidata - awgldk - TriplyDB

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q36848153

about

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma Thrombotic microangiopathy with targeted cancer agents The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review Combination therapy for renal cell cancer: what are possible options?Sunitinib in the treatment of metastatic renal cell carcinoma Approaches to modernize the combination drug development paradigm A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma Antineoplastic agents and thrombotic microangiopathy.Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial A phase I study of sunitinib plus bevacizumab in advanced solid tumors.Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in a patient with metastatic neuroendocrine tumour successfully treated with rituximab-CVP.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.Interleukin-6 in bone metastasis and cancer progression.Molecular diagnosis and therapy of kidney cancer.The Dark Side of the Moon - the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management.Anti-VEGF Cancer Therapy in Nephrology Practice A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies Efficacy and safety of everolimus in korean patients with metastatic renal cell carcinoma following treatment failure with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor.Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab Renal cell carcinoma: molecular biology and targeted therapy Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).The prospects of pazopanib in advanced renal cell carcinoma.Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.Future directions in renal cell carcinoma: 2011 and beyond New insights into the biology of renal cell carcinoma Therapeutic advances in women's cancers

P2860

Q24606852-A4E51554-F6BA-4510-8832-A9000B28A392 Q24635904-95DDD1CF-E05D-4669-B1B8-E78EAFEA32CC Q26740374-EF2E5F5A-5FEE-4E15-9408-D24296166FCE Q26774515-B2E2082A-24A2-4478-AD07-A03D3FC8F05E Q27011663-A50FFE31-FE00-4069-8F39-BB82E8EBA75F Q28072057-FBF5FD3E-39E0-473F-BD7F-E76C25C92AB5 Q28072074-223FCF8A-3969-4C6E-A367-73377A0BD8C8 Q28304566-3BB83F2B-D01C-4EFB-A678-9B83535BA3CC Q30251919-88898BF0-C97A-46FF-8149-BD91F7A3D7B3 Q30537414-872CFB51-2F2C-4DA5-9D6E-149297B0DCAC Q33386345-8481049A-05FA-4DED-8AF2-A268D7E2B373 Q33402349-B047ABB7-612C-441E-A7B5-FCEB26283E53 Q33408049-FC4CC15A-36AF-46F5-AF19-80A6721FD801 Q33414769-1168404D-2412-4453-B6D6-9AF0B40BC1FA Q33415397-2A5FA198-C765-462C-99C8-F68422B7684B Q33415842-BECD2983-3562-49EC-B2E1-7C2993C75C7B Q33417933-6D8F5D1A-FDD7-4595-AABD-1C7E9D12067B Q33423350-38D4162C-28D3-40B6-B983-6230C109C0A8 Q33606102-10DCD8DE-A464-431B-90E0-972C6EAAE49F Q33658626-C0E1D25C-DC97-48DA-9C69-A56A28F6ED14 Q33985467-5FD7D541-6DED-4747-8EA7-42D289BBBE64 Q34013801-05A52D7B-F037-415C-AC9E-779D4D7FAD96 Q34051820-CCE04A6B-B3D8-4B5D-8025-172D9769E3B5 Q34065685-9522D4EC-6F79-43A6-8BC9-AD82C2013069 Q34095802-51A2C2B3-E9F4-4ECC-A86B-57D6CE7E061D Q34152125-C88E2CC5-E8E7-4FFB-A94F-DAA499F3CF37 Q34356881-F1A2961A-3194-4568-8512-EC1DB2B21290 Q34386054-9CE3688E-D450-4DD7-8FF2-0A05D1714F2F Q34417804-7BE44838-EC73-4A05-9413-CCA04F1801C9 Q34513914-FDC3F0BD-DCEE-4FB5-AA39-E22D6A664132 Q34517849-8678934F-3CCE-4FD6-8C90-9C0D9A860532 Q34656393-9374418E-AC2E-4B28-BA34-7355A56FD1A8 Q34765380-936DB3B8-F0AC-488C-87EB-622B0818D316 Q34795914-6858AD9F-1404-468D-BE7A-C39120CEE625 Q34803030-6C556990-0337-48A9-93FB-0E5B4E5CEAC0 Q34956830-DE15EF10-8ED1-4DEA-8764-F228A9A99123 Q35050558-ED080AE8-9A37-47B5-A4F1-9EC20CDA234F Q35152107-6EBFFB7C-9E0D-474E-9703-51DDEABE1C21 Q35180400-0D1B6703-C6F3-424A-BB26-F886819311FD Q35418973-E86A2F84-4502-4127-885A-239EE8F4FAEB

P2860

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q36848153

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Phase I trial of bevacizumab p ...... tastatic renal cell carcinoma.

@en

type

label

Phase I trial of bevacizumab p ...... tastatic renal cell carcinoma.

@en

prefLabel

Phase I trial of bevacizumab p ...... tastatic renal cell carcinoma.

@en

P1433

Q36848153-B0AEBE56-D451-4825-84DF-0A71BAC55E58

P1476

Q36848153-3BC84396-1103-4D32-BA8F-DA3E0F9AC6B2

P2093

Q36848153-34549E1E-7F25-4E95-8A5D-F5EAA1962291

Q36848153-4EF9E2F4-6AB8-4FBD-ABD6-21B0050B44D8

Q36848153-6DDD1577-42CC-481C-A334-80347ACE88BB

Q36848153-7517B999-0B93-40F2-AB1F-3B780EE81076

Q36848153-B8425E97-5D99-4CE9-8000-4301894F9292

Q36848153-F2DB1191-6CED-48E5-8676-F604031BB685

Q36848153-F6E004D3-0979-4B02-8B0C-B15F007C2BEA

Q36848153-FA422412-D148-4BA9-8BAC-2A2780D3DF3F

Q36848153-FD6961A4-CCB6-4E9F-A3DA-00809CD47F42

P2860

Q36848153-2221A46A-8E08-4715-B1BB-A56E77CEDC12

Q36848153-236343EA-321E-486A-81DB-DBB51BEC153F

Q36848153-25402958-84E1-47CD-BAA6-7F0A45307002

Q36848153-26DCE1B6-B370-4786-B9AF-0B214DDB4BA2

Q36848153-2925DC7B-3F93-4B07-B173-8042FE7E6AEC

Q36848153-40434E57-DE0B-4AB5-9007-6D3DAC17FC9F

Q36848153-42FD6AD6-0ADE-4D43-B5BC-0C887BC8D25A

Q36848153-687DF31B-29A4-44B7-802A-9F3F51DCC3B1

Q36848153-731DF5C0-0685-4DF9-8031-9460A910095B

Q36848153-7F57B385-C81C-4D7D-90F2-50DD358AC8C9

P304

Q36848153-37B58F32-4730-4054-B2DD-C524688499A8

P31

Q36848153-0AB147F3-7C84-4BAD-8DD7-CA534A2903C5

P356

Q36848153-001DABCE-B40E-4D4E-8BE9-5F905D149CC1

P407

Q36848153-0B16EFE8-2F76-4307-A144-A200DC171220

P433

Q36848153-C08A18EE-4FFD-44F1-853D-879F6672286B

P478

Q36848153-953FF14B-BB4C-4C2D-B007-DD198FB8A63A

P50

Q36848153-2454A876-F79B-4394-BF4F-60D81FA36274

Q36848153-9EBA1BAB-F5EB-4B08-9E5F-CD7867D6EA42

P577

Q36848153-3F968C6D-D4DD-4DFD-A0C5-8B541706411C

P698

Q36848153-9732AF56-5137-45C0-AF8D-B4B9D4E1793A

P921

Q36848153-0CA190AE-BE07-4B75-B8B2-984CC4B2E6AD

Q36848153-93DF00BE-DE11-470F-BFAB-CF262ADB97F2

P932

Q36848153-F5F76A0F-368A-43B9-B75C-FF41C94FD4E8

P356

JCO.2008.19.0108

P1433

Journal of Clinical Oncology

P1476

Phase I trial of bevacizumab p ...... etastatic renal cell carcinoma

@en

P2093

Carlos D Flombaum

http://www.w3.org/2001/XMLSchema#string

Ellen Ronnen

http://www.w3.org/2001/XMLSchema#string

Hani Hassoun

http://www.w3.org/2001/XMLSchema#string

Michael S Baum

http://www.w3.org/2001/XMLSchema#string

Michelle S Ginsberg

http://www.w3.org/2001/XMLSchema#string

Nicole Ishill

http://www.w3.org/2001/XMLSchema#string

Patricia Fischer

http://www.w3.org/2001/XMLSchema#string

Sujata Patil

http://www.w3.org/2001/XMLSchema#string

Susanne Velasco

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibition and renal thrombotic microangiopathy

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

The von Hippel-Lindau tumor suppressor gene and kidney cancer

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

Sunitinib in patients with metastatic renal cell carcinoma.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

P304

1432-1439

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.19.0108

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Darren R Feldman

P577

2009-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19224847

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3655420

http://www.w3.org/2001/XMLSchema#string